Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 5/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.38 |
| ▸ | STK17B | O94768 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.35 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.35 |
| ▸ | USP1 | O94782 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371665 | 0.89 | JAK2 (0.51) | JAK2JAK3TLR7ADORA2AADORA1 | |
| SCHEMBL12371651 | 0.89 | JAK2 (0.45) | JAK2JAK3TLR7ADORA3ADORA2A | |
| SCHEMBL2270517 | 0.86 | JAK2 (0.47) | JAK2JAK3TLR7ADORA3USP1 | |
| SCHEMBL13608416 | 0.86 | TLR7 (0.47) | STK17ATLR7STK17BADORA3USP1 | |
| SCHEMBL13608238 | 0.86 | JAK2 (0.45) | JAK2JAK3ADORA3ADORA2AADORA1 | |
| SCHEMBL13608329 | 0.85 | HSP90AA1 (0.52) | JAK2JAK3STK17ATLR7STK17B | |
| SCHEMBL12371659 | 0.84 | TLR7 (0.40) | JAK2JAK3STK17ATLR7STK17B | |
| SCHEMBL12371765 | 0.83 | ADORA3 (0.53) | TLR7ADORA3USP1 | |
| SCHEMBL13608332 | 0.83 | JAK2 (0.46) | JAK2JAK3STK17ATLR7STK17B | |
| SCHEMBL12371666 | 0.83 | JAK2 (0.44) | JAK2JAK3STK17ASTK17BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PRKCE, PRKCH, PRKCQ | JAK2 735/4885JAK3 719/4885STK17A 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.